Answers are grounded in this paper and cite their sources.
Randomised controlled trial assesses digital self-management intervention for IBD outcomes, suggesting cost-effective benefits.
Background Managing fatigue, pain and urgency/ faecal incontinence (FI) represents a key unmet need in holistic treatment of IBD. The IBD-BOOST programme was a 5-year programme evaluating the burden and treatment of these symptoms. Methods A national survey was conducted [1], followed by development and feasibility testing of a checklist for nurse-led optimisation of modifiable causes of symptoms [2]. Following this, IBD-BOOST, a digital, interactive, facilitator-supported, self-management intervention to address fatigue, pain and FI was assessed in a multi-centre, two-arm, parallel-group, randomised controlled trial [3]. The web-based programme combined educational, behavioural and cognitive strategies delivered through a cognitive behavioural framework. Patients who rated impact of fatigue, pain, and/or FI as ≥ 5/10 in the national survey were invited. The intervention was 6 months access to the online IBD-BOOST programme supported by a facilitator; the control group received are as usual (CAU). Primary outcomes were UK Inflammatory Bowel Disease Questionnaire (UK-IBDQ) and global rating of symptom relief (GRSR) at 6 months. A cost-effectiveness analysis was performed. Results From the national survey (8486 responses; 54% reporting FI, 24% fatigue and 21% pain)[1], 780 participants were recruited to the RCT. At 6 months, there were no statistically significant between-arm differences for UK-IBDQ (mean difference = -1.67 (95%CI = -4.13, 0.80), p = 0.19) and GRSR (mean difference = 0.44 (95%CI = -0.56, 1.44), p = 0.39), but positive trends across outcomes were observed. Engagement with the programme was variable, with 57% of participants completing the minimum “dose” of four sessions. Importantly, complier-averaged causal effects analysis demonstrated that participants who complied with the intervention reported better UK-IBDQ scores than ‘would-be’ compliers receiving CAU alone (mean difference = -2.39 (95%CI = -4.34, -0.45), p = 0.02). Serious adverse events were similar between the intervention and CAU. The intervention was found to be cost-effective, improving generic health-related QoL (EQ-5D-5L) with high probability (>90%) of being cost-effective at conventional willingness-to-pay thresholds. Cost savings were -£28,633 (95% CI: -51,555; 18,764) and -£33,568 (-64,421; 26,198) per QALY gained with IBD-BOOST from health services and societal perspectives, respectively. Conclusion The IBD BOOST programme represents an in-depth body of work in holistic IBD care. The RCT is the largest trial of a psychological intervention in IBD fatigue, pain and FI. Although the primary outcome endpoints were not met, patients who engaged with the intervention derived benefit and the intervention was cost-effective. References: 1. Fatigue, pain and faecal incontinence in adult inflammatory bowel disease patients and the unmet need: a national cross-sectional survey. BMC Gastroenterology, 2024. 24: p. https://doi.org/10.1186/s12876-024-03570-8. 2. Optimising fatigue, abdominal pain and faecal incontinence in people with inflammatory bowel disease (IBD-BOOST Optimise): feasibility study of a checklist and algorithm for initial nurse-led management. BMJ Open Gastroenterology, 2024. doi:10.1136/bmjgast-2024-001585. 3. Supported online self-management versus care as usual for symptoms of fatigue, pain and urgency/incontinence in adults with inflammatory bowel disease (IBD-BOOST): study protocol for a randomised controlled trial. Trials. 2021 Aug 3;22(1):516. doi: 10.1186/s13063-021-05466-4 Conflict of interest: Hart, Ailsa: Grant: Takeda Personal Fees: Abbvie, Amgen, Arena, AZ, Falk, Celltrion, Eli Lilly, Ferring, Genentech/ Roche, GSK, Pfizer, Takeda, Napp, Pharmacosmos, Janssen (J & J), Bristol-Myers Squibb, Gilead, Galapagos Norton, Christine: Personal Fees: Janssen: lecture fee WebMD lecture fee Medscape symposium fee Merck Pharmaceuticals lecture fee Pfizer advisory board fee Moss-morris, Rona: No conflict of interest Mihaylova, Borislava: No conflict of interest Cléirigh Büttner, Fionn: No conflict of interest Hamborg, Thomas: No conflict of interest Miller, Laura: No conflict of interest Roukas, Chris: None Stagg, Imogen: No conflict of interest Aziz, Qasim: Grant: Classado Pharmaceuticals Takeda Pharmaceuticals Other: My Health Chart - Med Tech Czuber-Dochan, Wladyslawa: Grant: National Institute of Health Research, Bristol Myers Squibb, and Crohn’s and Colitis UK Personal Fees: Dr Falk Pharma UK and PharmaCosmos Dibley, Lesley: No conflict of interest McGuiness, Serena: No conflict of interest Pollok, Richard: I have no potential Conflict of Interest in the past 3 years including grants, honoraria, shares, paid positions, advisory boards, personal fees or non-financial support Saxena, Sonia: No conflict of interest Sweeney, Louise: No conflict of interest Taylor, Stephanie: No conflict of interest Wileman, Vari: No conflict of interest Lindsay, James: Investigator Initiated Research Grant: Takeda, Abbvie, Gilead Personal Fees: I have received fees for speaking and may have received support to attend academic conferences from: Abbvie UK/Global, Bristol Myers Squib, Cornerstones US, Gilead, Galapagos, Lilly, MSD UK, Ferring UK, Ferring Intl., Celltrion, Takeda, Pfizer, Janssen, Tillotts, Other: I serve of the advisory board of Abbvie UK/Global, Alpini, Astra Zeneca, Engytix, Galapagos, Gilead, GSK, Lily, MSD, Ferring UK, Ferring Intl., Celltrion, Takeda, Pfizer, Janssen, Shattucks Laboratory,
No takes yet. Share an insight, caveat, or question.
Hart et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: